Personalized Screening for Breast Cancer: A Wolf in Sheep's Clothing?

Abstract

1365 lifetime risk group [7]. ACR and SBI do not currently advocate ultrasound screening because of the low biopsy positive predictive value of 8–9%, its operator dependence, the lengthy examination time for handheld ultrasound, and the limited availability of breast ultrasound technologists [1]. However, ACR and SBI guidelines state that adjunctive screening ultrasound may be considered for women having dense breasts [1]. Automated ultrasound systems reduce both examination time and operator dependence and seem to yield detection rates similar to handheld ultrasound; however, recall rates and falsepositive biopsy rates remain high [8].